ASCO guideline update (12 phase III RCTs) for advanced gastroesophageal cancer: immunotherapy plus chemotherapy for pMMR/MSS HER2-negative disease with PD-L1 ≥1, zolbetuximab for CLDN18.2-positive PD-L1 <1, and trastuzumab-based therapy for HER2-positive disease.
Guidelinen = 12 trials
Shah et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update